Cocrystal Pharma, Inc.
COCPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. With a market capitalization of $21.8M, it sits in micro-cap territory. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Market Cap
$21.8M
Beta
1.48
P/E (TTM)
—
P/E (Fwd)
-1.95
EPS (TTM)
$-0.75
EPS (Fwd)
$-0.58
ROE
-311.7%
ROA
-96.1%
Cash
$2.2M
Total Debt
$1.3M
Free CF
-$4.3M
52W Change
-22.1%
Annual Financials
Cash vs Debt
Where COCP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, COCP finished 4.50% above its 150-day moving average ($1.11) and 6.42% above its 200-day moving average ($1.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is COCP overbought or oversold?
At the September 3, 2026 close, COCP's RSI(14) was 56.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.2M in cash and $1.3M in debt, COCP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$4.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -311.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cocrystal Pharma, Inc. and its sector.